Insulin Glargine Research: What 3,587 Studies Show (2026) | RetatrutideCompare

Insulin Glargine — 3,587 studies indexed on PubMed. Long-acting basal insulin analog. pH-dependent solubility creates a depot in subcutaneous tissue. Half-life: ~12 hours (effective duration ~24 hours). FDA status: FDA-approved (2000).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Insulin Glargine?

There are approximately 3,587 studies indexed on PubMed that mention Insulin Glargine (Lantus, Toujeo), based on a search last updated 2026-06-18.

Is Insulin Glargine FDA-approved?

FDA status: FDA-approved (2000).

How does Insulin Glargine work?

Long-acting basal insulin analog. pH-dependent solubility creates a depot in subcutaneous tissue.

Long-acting basal insulin analog. pH-dependent solubility creates a depot in subcutaneous tissue.

Reference facts

Also known as
Lantus, Toujeo, Basaglar
Category
Hormonal & Pituitary
Mechanism of action
Long-acting basal insulin analog. pH-dependent solubility creates a depot in subcutaneous tissue.
Targets
Insulin receptor
Indications under research or approved
Diabetes type 1 and 2 — basal insulin replacement
Regulatory status (reference entry)
FDA-approved (2000)
Half-life
~12 hours (effective duration ~24 hours)
Sequence
GIVEQCCTSICSLYQLENYCG
Sequence notes
Modified insulin: A-chain Asn21 → Gly; B-chain extended with Arg-Arg at C-terminus, forming microprecipitates at neutral subcutaneous pH for prolonged release.
Molecular weight (Da)
6063
Originator / sponsor
Sanofi (Lantus); Eli Lilly (Basaglar biosimilar)
First reported
1996

Primary References

Explore research articles about Insulin Glargine

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.